Harrow Inc. (HROW), a provider of ophthalmic disease management solutions, said Friday it has agreed to acquire its former subsidiary, Melt Pharmaceuticals, Inc.
Financial terms of the deal were not disclosed.
Melt's lead investigational therapy, MELT-300, is a patented sublingual formulation combining fixed doses of midazolam and ketamine to provide rapid, predictable sedation and analgesia.
In November 2024, Melt reported positive topline results from its pivotal LOUISE Phase 3 trial, showing MELT-300 was statistically superior to both sublingual midazolam alone and placebo in achieving successful procedural sedation.
Harrow said it plans to submit a New Drug Application (NDA) for MELT-300 to the FDA in 2027, with a potential U.S. launch targeted for 2028.
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.